ES2627217T3 - Partículas micropulverizadas cristalinas - Google Patents

Partículas micropulverizadas cristalinas Download PDF

Info

Publication number
ES2627217T3
ES2627217T3 ES08752990.5T ES08752990T ES2627217T3 ES 2627217 T3 ES2627217 T3 ES 2627217T3 ES 08752990 T ES08752990 T ES 08752990T ES 2627217 T3 ES2627217 T3 ES 2627217T3
Authority
ES
Spain
Prior art keywords
particles
crystalline particles
particle diameter
crystalline
distribution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08752990.5T
Other languages
English (en)
Inventor
Masahiro Akimoto
Toshikazu Komagata
Motohiro Shiraki
Akihiro Ando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2627217T3 publication Critical patent/ES2627217T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Partículas cristalinas de N-(17-ciclopropilmetil-4,5α-epoxi-3,14-dihidroximorfinan-6ß-il)-ftalimida o una de sus sales farmacéuticamente aceptables, obteniéndose las partículas cristalinas moliendo finamente N-(17-ciclopropilmetil-4,5α-epoxi-3,14-5 dihidroximorfinan- 6ß-il)-ftalimida cristalina o una de sus sales farmacéuticamente aceptables con un molino de energía fluida o un molino de impacto, teniendo las partículas cristalinas un grado de cristalinidad de no menos del 85 %; y siendo las partículas cristalinas de cualquiera del siguiente tipo (a) o el siguiente tipo (b): (a) partículas cristalinas que tienen una distribución del diámetro de partícula en la que un diámetro de partícula (D50) en el punto en el que la frecuencia acumulativa de la distribución volumétrica calculada de forma acumulativa de partículas que tienen un diámetro más pequeño alcanza el 50 % está dentro de un intervalo de 1 a 30 μm, y un diámetro de partícula (D90) en el punto en el que la frecuencia acumulativa de la distribución volumétrica calculada de forma acumulativa de partículas que tienen un diámetro más pequeño alcanza el 90 % es no superior a 90 μm; (b) partículas cristalinas que tienen una distribución del diámetro de partícula en la que la frecuencia acumulativa de la distribución volumétrica ocupada por partículas que tienen un diámetro de partícula basado en el volumen no superior a 15 μm es no inferior al 40 %.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
12
imagen12
imagen13

Claims (1)

  1. imagen1
ES08752990.5T 2007-05-21 2008-05-20 Partículas micropulverizadas cristalinas Active ES2627217T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007133691 2007-05-21
JP2007133691 2007-05-21
PCT/JP2008/059194 WO2008143239A1 (ja) 2007-05-21 2008-05-20 結晶性微粉化粒子

Publications (1)

Publication Number Publication Date
ES2627217T3 true ES2627217T3 (es) 2017-07-27

Family

ID=40031936

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08752990.5T Active ES2627217T3 (es) 2007-05-21 2008-05-20 Partículas micropulverizadas cristalinas

Country Status (9)

Country Link
US (1) US8198446B2 (es)
EP (1) EP2156837B1 (es)
JP (1) JP5564943B2 (es)
KR (1) KR101546398B1 (es)
CN (1) CN101965187B (es)
AU (1) AU2008254037B2 (es)
CA (1) CA2687955C (es)
ES (1) ES2627217T3 (es)
WO (1) WO2008143239A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
CN114105839A (zh) * 2020-08-27 2022-03-01 湖北舒邦药业有限公司 一种原料药的前处理方法及其组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000492A1 (fr) * 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha DERIVE D'ACIDE L-α-AMINOADIPIQUE EN POUDRE FINE, PREPARATIONS SOLIDES ORALES CONTENANT LEDIT DERIVE ET PROCEDE DE TRAITEMENT DE POUDRES EN VRAC
JP2004511439A (ja) * 2000-08-14 2004-04-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 微粉化したトルセミド
JP3939601B2 (ja) * 2001-06-20 2007-07-04 株式会社アクティバスファーマ キノリノン誘導体医薬組成物及びその製造方法
ES2479042T3 (es) 2002-10-09 2014-07-23 Toray Industries, Inc. Remedios o agentes preventivos de la incontinencia urinaria y derivados de morfinano que presentan un grupo heterocíclico que contiene nitrógeno
BRPI0408403A (pt) * 2003-03-21 2006-03-21 Dsm Ip Assets Bv pó cristalino de triidrato de amoxicilina
US7718664B2 (en) * 2004-03-30 2010-05-18 Toray Industries, Inc. Anti-itching agent
TW200621785A (en) * 2004-11-04 2006-07-01 Toray Industries Analgesic
WO2007055184A1 (ja) * 2005-11-09 2007-05-18 Toray Industries, Inc. 機能性腸障害の治療または予防剤
CN101340911B (zh) 2005-12-21 2013-01-02 东丽株式会社 镇咳剂

Also Published As

Publication number Publication date
EP2156837A4 (en) 2012-12-05
EP2156837B1 (en) 2017-04-26
US20100160634A1 (en) 2010-06-24
CA2687955C (en) 2015-06-30
JP5564943B2 (ja) 2014-08-06
CA2687955A1 (en) 2008-11-27
AU2008254037A1 (en) 2008-11-27
AU2008254037B2 (en) 2013-10-17
CN101965187B (zh) 2012-11-21
WO2008143239A1 (ja) 2008-11-27
KR20100056424A (ko) 2010-05-27
US8198446B2 (en) 2012-06-12
CN101965187A (zh) 2011-02-02
JPWO2008143239A1 (ja) 2010-08-12
EP2156837A1 (en) 2010-02-24
KR101546398B1 (ko) 2015-08-26

Similar Documents

Publication Publication Date Title
ES2627217T3 (es) Partículas micropulverizadas cristalinas
ES2550634T3 (es) Uso de nanocristales para un balón de suministro de fármaco
CL2017001724A1 (es) Dispositivo de fijacion de un elemento de desgaste o proteccion en una pala de una maquina de movimiento de tierras y procedimiento de fijacion y sistema de desgaste o proteccion correspondientes
IN2014CN03259A (es)
AR091259A1 (es) Formas solidas de un compuesto antiviral
WO2011158244A3 (en) Self cleaning shunt
IN2012DN03337A (es)
IT1400090B1 (it) Procedimento a basso consumo energetico per la produzione di melammina ad elevata purezza tramite pirolisi dell'urea, e relativa apparecchiatura
AU327995S (en) Vacuum cleaner cyclone module
IN2012DN01232A (es)
IN2015DN03191A (es)
WO2011087705A3 (en) Fine particle croscarmellose and uses thereof
USD738529S1 (en) Garden fence pouch
GB2487700A (en) Improved silver oxide formulations
Shim et al. The Status and Improvement of Hydrological Survey Standardization
ES2553609T3 (es) Laminados que contienen minerales duros, en forma de placas
WO2011066390A3 (en) Nanoscale adjuvants and related pharmaceutical compositions and methods
TW200716099A (en) Hydrates of alkaline earth metal salts of irbesartan and their preparation
Indonesia Harvested Area of Mungbean by Province (ha), 1997–2015
Goldman et al. Terapia fotodinámica
CN104626078A (zh) 与墙体固定牢固的工具柜
FR2965635B1 (fr) Telemetre hyperfrequence et reflecteur associe equipe d'un inclinometre
Kim English Journal: the Destination of Korean Journal of Family Medicine?.
Jang et al. Retraction of Highly Enantioselective Radical Addition to N-Benzoyl Hydrazones Using Chiral Ammonium Salts
AU315736S (en) Camera